Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China: A Retrospective Real-world Study (REHEARSAL)

NCT06585501 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06585501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06585501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China: A Retrospective Real-world Study (REHEARSAL)
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Completed
Start date
August 15, 2024
Completion date
July 30, 2025
Enrollment
805 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction cancer